2023 World Conference on Lung Cancer (Posters)-P1.23. Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer

P1.23. Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the clinical utility of performing both tissue and plasma next-generation sequencing (NGS) to detect actionable alterations (AA) in patients with advanced non-small cell lung cancer (aNSCLC). The study involved two cohorts of aNSCLC patients who were prospectively assessed with tissue and plasma NGS at diagnosis. The Oncomine Focus Assay, Guardant360 CDx, and FoundationOne Liquid CDx were used for the analysis. <br /><br />The results showed that AA were detected in 39% of patients in cohort 1 and 44% of patients in cohort 2. Of the patients with AA, 54% of cohort 1 and 43% of cohort 2 had AA detected in both plasma and tissue, while 28% of cohort 1 and 34% of cohort 2 had AA detected only in plasma, and 18% of cohort 1 and 23% of cohort 2 had AA detected only in tissue. <br /><br />In the cases where AA were only detected in plasma, some had non-informative tissue results, while others had informative tissue results. Similarly, in the cases where AA were only detected in tissue, some had uninformative plasma results, while others had informative plasma results. <br /><br />Based on these findings, the study concludes that combined tissue and plasma NGS can increase the detection of AA in newly diagnosed aNSCLC when AA are not detected by one of these assays. The study also suggests that if AA are not detected by tissue, plasma NGS should be considered, and vice versa, due to the observed discordant data. <br /><br />Overall, the study highlights the potential clinical utility of combining tissue and plasma NGS in the detection of actionable alterations in aNSCLC patients.

Asset Subtitle

Helena Bote de Cabo

Meta Tag

Speaker Helena Bote de Cabo

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

clinical utility

tissue NGS

plasma NGS

detect actionable alterations

advanced non-small cell lung cancer

Oncomine Focus Assay

Guardant360 CDx

FoundationOne Liquid CDx

cohort 1

cohort 2